First Trust NYSE Arca Biotechnology Index Fund (FBT)

Key Metrics

TER 55.00% per year

Distribution policy Accumulating

Fund size USD 2,270 M

Inception date June 19, 2006

Holdings 32

Fund currency USD

Fund domicile US

Provider First Trust

For full official fund details, factsheets, and holdings, visit ftportfolios.com (opens in new tab).

Historical Return

Last updated: Jun 15, 2026

1 Year +39.4%

3 Years (avg.) +12.2%

5 Years (avg.) +5.5%

Risk & Analysis Metrics

Last updated: Jun 15, 2026

Volatility

20.05% 1 Year

20.09% 3 Years

21.53% 5 Years

23.72% 10 Years

Max Drawdown

-14.26% 1 Year

-20.05% 3 Years

-29.95% 5 Years

-33.28% 10 Years

Sharpe Ratio

1.38 1 Year

0.43 3 Years

0.15 5 Years

0.32 10 Years

Return Triangle (Heatmap)

Last updated: Jun 15, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	-17.1%	7.4%	18.7%	25.2%	22.1%	14.4%	17.2%	14.5%	15.1%	14.9%	13.1%	11.4%	10.7%	10.2%	11.1%
2012		39.2%	42.1%	43.7%	34.5%	22.0%	24.1%	19.9%	19.9%	19.2%	16.7%	14.5%	13.4%	12.7%	13.4%
2013			45.2%	46.0%	33.0%	18.1%	21.3%	17.0%	17.4%	16.9%	14.4%	12.2%	11.4%	10.7%	11.7%
2014				46.8%	27.3%	10.2%	16.0%	12.0%	13.3%	13.3%	11.0%	9.1%	8.4%	8.0%	9.3%
2015					10.3%	-4.5%	7.3%	4.7%	7.6%	8.5%	6.7%	5.1%	4.8%	4.7%	6.4%
2016						-17.3%	5.8%	2.9%	6.9%	8.2%	6.1%	4.4%	4.2%	4.1%	6.0%
2017							35.3%	14.8%	16.5%	15.7%	11.5%	8.5%	7.7%	7.2%	8.9%
2018								-2.5%	8.1%	9.8%	6.3%	3.8%	3.7%	3.7%	6.0%
2019									19.9%	16.6%	9.4%	5.5%	5.0%	4.8%	7.3%
2020										13.3%	4.5%	1.1%	1.5%	2.0%	5.3%
2021											-3.6%	-4.6%	-2.1%	-0.7%	3.8%
2022												-5.5%	-1.4%	0.3%	5.8%
2023													2.9%	3.3%	9.8%
2024														3.7%	13.4%
2025															24.0%

Distributions

*by ETF Portfolio Weight Last updated: Jun 15, 2026

Profit Margin Distribution

< 0%

21%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

20%

1y 3y N/A N/A

10 - 15%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

17%

1y 3y N/A N/A

30 - 40%

18%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

18%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

1y 3y N/A N/A

15 - 20

18%

1y 3y N/A N/A

20 - 25

18%

1y 3y N/A N/A

25 - 35

1y 3y N/A N/A

35 - 50

18%

1y 3y N/A N/A

> 50

16%

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

2.0%

1y 3y N/A N/A

Small Cap

3.2%

1y 3y N/A N/A

Mid Cap

28.1%

1y 3y N/A N/A

Large Cap

66.7%

1y 3y N/A N/A

Mega Cap

0.0%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Jun 21, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$34.6B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	0.26%	2.03%
Beta Indicates the relationship between the price performance of a share and the market.	0.67	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	43.24	28.29
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-49.14	-
Profitable Companies	83%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	32.03	14.56
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	7.59	8.28
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	8.88	10.72

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	12.44	21.15
Enterprise Value to Revenue Enterprise value divided by revenue	7.1	8.72
Total Debt to Enterprise Value Total debt divided by enterprise value	0.08	0.05
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.69	0.33
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	7.33%	-6.18%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-25.3%	-117.9%
Return on Equity Equity divided by market cap.	19.97%	1.23%
Return on Assets Indicates a company's profitability in relation to its total assets.	6.34%	3.29%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	7.42%	3.31%

Sectors

Manufacturing	82.9%
Professional, Scientific, and Technical Services	11.4%
Health Care and Social Assistance	5.8%
Other	0.0%

Countries

United States	84.8%
Ireland	3.9%
Netherlands	3.3%
Germany	2.8%
Denmark	2.6%
Switzerland	2.5%
Other	0.0%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Moderna Inc

MRNA - Manufacturing

Market Cap $25.38B

P/E Ratio -7.9

Dividends 0.0%

Total Investment $119.45M

Weight 5.26%

Loading details…

United Therapeutics Corp

UTHR - Manufacturing

Market Cap $22.78B

P/E Ratio 18.1

Dividends 0.0%

Total Investment $98.94M

Weight 4.36%

Loading details…

Alkermes plc

ALKS - Manufacturing

Market Cap $7.5B

P/E Ratio 48.4

Dividends 0.0%

Total Investment $96.15M

Weight 4.24%

Loading details…

Gilead Sciences, Inc.

GILD - Manufacturing

Market Cap $153.66B

P/E Ratio 16.7

Dividends 2.6%

Total Investment $92.82M

Weight 4.09%

Loading details…

Axsome Therapeutics Inc

AXSM - Manufacturing

Market Cap $12.89B

P/E Ratio -67.2

Dividends 0.0%

Total Investment $88.21M

Weight 3.89%

Loading details…

AMGEN Inc.

AMGN - Manufacturing

Market Cap $182.21B

P/E Ratio 23.3

Dividends 2.9%

Total Investment $87.01M

Weight 3.83%

Loading details…

Corcept Therapeutics Inc

CORT - Manufacturing

Market Cap $8.58B

P/E Ratio 177.6

Dividends 0.0%

Total Investment $86.69M

Weight 3.82%

Loading details…

Krystal Biotech Inc

KRYS - Manufacturing

Market Cap $10.26B

P/E Ratio 45.3

Dividends 0.0%

Total Investment $79.69M

Weight 3.51%

Loading details…

Biogen Inc

BIIB - Manufacturing

Market Cap $29.02B

P/E Ratio 21.0

Dividends 0.0%

Total Investment $78.8M

Weight 3.47%

Loading details…

Exelixis Inc

EXEL - Professional, Scientific, and Technical Services

Market Cap $13.05B

P/E Ratio 16.6

Dividends 0.0%

Total Investment $78.54M

Weight 3.46%

Loading details…

Neurocrine Biosciences, Inc.

NBIX - Manufacturing

Market Cap $15.92B

P/E Ratio 23.8

Dividends 0.0%

Total Investment $78.24M

Weight 3.45%

Loading details…

Regeneron Pharmaceuticals, Inc.

REGN - Manufacturing

Market Cap $62.84B

P/E Ratio 14.3

Dividends 0.6%

Total Investment $78.23M

Weight 3.45%

Loading details…

Vertex Pharmaceuticals, Inc.

VRTX - Manufacturing

Market Cap $114.63B

P/E Ratio 26.5

Dividends 0.0%

Total Investment $77.62M

Weight 3.42%

Loading details…

Biomarin Pharmaceutical Inc. - Registered Shares

BMRN - Manufacturing

Market Cap $10.57B

P/E Ratio 39.1

Dividends 0.0%

Total Investment $77.28M

Weight 3.40%

Loading details…

Argen X SE - ADR

ARGX - Manufacturing

Market Cap $54.32B

P/E Ratio 49.7

Dividends 0.0%

Total Investment $74.72M

Weight 3.29%

Loading details…

Sarepta Therapeutics Inc

SRPT - Manufacturing

Market Cap $1.85B

P/E Ratio 28.3

Dividends 0.0%

Total Investment $73.64M

Weight 3.24%

Loading details…

Halozyme Therapeutics Inc.

HALO - Manufacturing

Market Cap $8.13B

P/E Ratio 23.5

Dividends 0.0%

Total Investment $71.92M

Weight 3.17%

Loading details…

BioNTech SE - ADR

BNTX - Manufacturing

Market Cap $22.98B

P/E Ratio -15.7

Dividends 0.0%

Total Investment $71.79M

Weight 3.16%

Loading details…

Incyte Corp.

INCY - Professional, Scientific, and Technical Services

Market Cap $19.62B

P/E Ratio 13.7

Dividends 0.0%

Total Investment $71.03M

Weight 3.13%

Loading details…

BeiGene Ltd - ADR

BGNE - Manufacturing

Market Cap $20.21B

P/E Ratio 4.0

Dividends 0.0%

Total Investment $70.88M

Weight 3.12%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna Stock Rallies. This Big Risk Just Got Eliminated.

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Moderna Inc

Moderna Inc

United Therapeutics Corp

United Therapeutics Corp

Alkermes plc

Alkermes plc

Gilead Sciences, Inc.

Gilead Sciences, Inc.

Axsome Therapeutics Inc

Axsome Therapeutics Inc

AMGEN Inc.

AMGEN Inc.

Corcept Therapeutics Inc

Corcept Therapeutics Inc

Krystal Biotech Inc

Krystal Biotech Inc

Biogen Inc

Biogen Inc

Exelixis Inc

Exelixis Inc

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Biomarin Pharmaceutical Inc. - Registered Shares

Biomarin Pharmaceutical Inc. - Registered Shares

Argen X SE - ADR

Argen X SE - ADR

Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc.

BioNTech SE - ADR

BioNTech SE - ADR

Incyte Corp.

Incyte Corp.

BeiGene Ltd - ADR

BeiGene Ltd - ADR

Cookie Settings